Drugs A – Z categorizes all the available medicines by alphabetical order.
Skyrizi vs Tremfya (Risankizumab Vs Guselkumab) is a comparison of the two monoclonal antibodies which selectively target and block Interleukin-23. IL-23 is an inflammatory cytokine that activates CD4 + T-helper (Th17) cell pathway to activate the inflammation cascade that is responsible for psoriatic plaque formation. Both of these drugs are indicated in the treatment of … Read more
Plerixafor is a class of drugs called hematopoietic stem cell mobilizer. When combined with filgrastim, a colony stimulating factor, it mobilizes CD-34 positive cells that have repopulating capabilities. Indications of Plerixafor: It is a used to mobilize hematopoietic cells (HSCs) which are then used for collection and subsequent autologous transfer (in combination with filgrastim), in … Read more
Simponi vs Cimzia is a comparison of the two novel TNF-inhibitors. Both the drugs can be administered as slow intravenous infusions or subcutaneous injections. This article explains the comparative pharmacokinetics, mechanism of action, and efficacies of two TNF inhibitors Simponi (golimumab) and Cimzia (certolizumab) in various conditions. Both of these drugs are indicated in chronic … Read more
Simponi vs Remicade is a comparison between two drugs Simponi (Golimumab) and Remicade (Infliximab). Both of them are TNF (Tumor Necrosis Factor) Inhibitors. These drugs aid in the treatment of chronic inflammation in various conditions. This comparison is based on the mechanism of action, pharmacokinetics, and efficacy in different conditions. Indications and Uses: Simponi vs … Read more
Rituximab Vs Infliximab is a comparison of the two drugs. Rituximab is a monoclonal antibody that targets CD-20 Positive B Lymphocytes While Infliximab is a TNF Inhibitor. Drug Description: Rituximab Vs Infliximab: Rituximab Infliximab Class Monoclonal type I CD20 antibody Tumor necrosis factor (TNF-alpha or TNF-α) blocker Chimeric Monoclonal IgG1 antibody Trade Names MabThera, Rixathon, … Read more
Nintedanib (Ofev) is a small tyrosine kinase inhibitor that is used to treat patients with idiopathic pulmonary fibrosis, interstitial lung disease in patients with systemic sclerosis, and non-small cell lung cancer. Overview of Nintedanib and its indications: Nintedanib (Ofev) is a small tyrosine kinase inhibitor that primarily targets platelet-derived growth factor receptors (PDGFR), Fibroblast growth … Read more
Simponi Vs Humira (Golimumab vs Adalimumab) is a comparison of the two novel TNF inhibitors. Both of these drugs are TNF (Tumor Necrosis Factor) Inhibitors. Their function is to reduce inflammation in different disease conditions. These two drugs will be compared based on the mechanism of action, dosage formulations, pharmacokinetics, and efficacy in different conditions. Indications … Read more
Lubiprostone is marketed by the brand name Amitiza. It is a locally acting drug that primarily activates the intestinal chloride channels and increases the fluid in the digested food, relieving constipation. Unlike Trulance and Linzess (Plecanatide and Linaclotide), Amitiza (Lubiprostone) acts on the chloride channels and activates them. Trulance and Linzess are drugs used for … Read more
Trulance VS Linzess (Plecanatide Vs Linaclotide) are two novel medicines that are being increasingly used to treat patients with chronic idiopathic constipation and Irritable bowel syndrome with predominant symptoms of constipation. Trulance Vs Linzess (Plecanatide Vs Linaclotide) What is Trulance? Trulance is the brand name of Plecanatide. It relieves constipation by acting as a guanylate … Read more
Simponi vs Enbrel is a comparison of the two TNF-inhibitors, Golimumab and Etanercept. Both Simponi (Golimumab) and Enbrel (Etanercept) aim to reduce the process of inflammation by decreasing the production of Interleukin-6 and Interleukin-8. Owing to their strong immune-modulatory effects, these drugs are commonly used to treat autoimmune rheumatic conditions like ankylosing spondylitis, psoriatic arthritis, … Read more